Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with FOLFIRI for the Treatment of Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with FOLFIRI for the Treatment of Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Lunresertib (Primary)
  • Indications Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms MINOTAUR
  • Sponsors Repare Therapeutics

Most Recent Events

  • 30 Jun 2024 According to a Repare Therapeutics media release, data from this trial presented at the ESMO GI Cancers Congress in June 2024.
  • 26 Jun 2024 According to a Repare Therapeutics media release, 38 patients were enrolled in the clinical trial as of May 2, 2024, the cutoff date for the data presented at ESMO GI Cancers Congress.
  • 26 Jun 2024 According to a Repare Therapeutics media release, Elisa Fontana, M.D., Ph.D., Medical Director, Sarah Cannon Research Institute UK will be presenting the initial positive results, in a mini oral presentation at the ESMO GI Cancers Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top